Patent application number | Description | Published |
20080293721 | ARYLTHIOACETAMIDE CARBOXYLATE DERIVATIVES AS FKBP INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISEASES - The present invention provides compounds having the general structure I, or a pharmaceutically acceptable salt thereof: | 11-27-2008 |
20090054348 | BI-DENTATE COMPOUNDS AS KINASE INHIBITORS - The present invention provides compound having the general structure A or pharmaceutically acceptable salts thereof: | 02-26-2009 |
20100016292 | INHIBITORS OF LETHAL FACTOR PROTEASE - The invention provides compounds that can efficiently and specifically inhibit bacterial toxins, such as inhibit the lethal factor (LF) protease activity of anthrax toxin and/or botulinum neurotoxin type A. The invention also provides methods for inhibiting proteases, such as lethal factor protease, as well as methods for treating bacterial infections, such as anthrax and botulinum. | 01-21-2010 |
20100041653 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS - The present disclosure provides compounds having the general structure A or pharmaceutically acceptable salts thereof: | 02-18-2010 |
20100240594 | TARGETED DELIVERY OF CHEMOTHERAPEUTIC AGENTS - The disclosure provides compounds and compositions, and methods of using these compounds and compositions, for the targeted delivery of chemotherapeutic agents. | 09-23-2010 |
20100240720 | ALLOSTERIC JNK INHIBITORS - The disclosure provides compounds and compositions, and methods of using these compounds and compositions, for the targeted delivery of chemotherapeutic agents. | 09-23-2010 |
20100261788 | Inhibition of Bid-Induced Cell-Death Using Small Organic Molecules - Various phenylamine derivatives are described as well as the use of compounds to inhibit BID protein for controlling apoptotic cascade. | 10-14-2010 |
20100298390 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN - The present invention provides compounds that efficiently and specifically inhibit lethal factor (LF) protease activity of anthrax toxin. | 11-25-2010 |
20110111057 | Methods and Compounds Useful to Induce Apoptosis in Cancer Cells - The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative. | 05-12-2011 |
20110172164 | BI-DENTATE COMPOUNDS AS KINASE INHIBITORS - The present disclosure provides compound having the general structure A or pharmaceutically acceptable salts thereof: | 07-14-2011 |
20120004311 | OPTICALLY PURE APOGOSSYPOL DERIVATIVE AS PAN-ACTIVE INHIBITOR OF ANTI-APOPTOTIC B-CELL LYMPHOMA/LEUKEMIA-2 (BCL-2) - A compound of Formula I: | 01-05-2012 |
20120190707 | SELECTIVE INHIBITORS OF AKT AND METHODS OF USING SAME - The present invention describes an improved method for screening compounds for activity in inhibiting the enzymatic activity of Akt1 protein kinase. In general, the method comprises: (1) providing a plurality of compounds suspected of having Akt1 kinase inhibitory activity; (2) modeling the docking of each of the plurality of the compounds with a target binding site; (3) ranking the docked compounds by goodness of fit; (4) further selecting compounds; (5) optionally, visually analyzing structures of compounds selected in step (4) to remove any compounds with improbable docking geometry; and (6) experimentally testing the selected compounds from step (4) or step (5), if step (5) is performed, to determine their inhibitory activity against Akt1. The invention also encompasses pharmaceutical compositions including compounds whose inhibitory activity against Akt1 is discovered by the screening method, as well as methods of use of the pharmaceutical compositions to prevent and treat cancer and other conditions. | 07-26-2012 |